Accuray Incorporated (ARAY) Receives Price Target

Accuray Incorporated (ARAY) : Currently there are 4 street experts covering Accuray Incorporated (ARAY) stock. The most bullish and bearish price target for the stock is $12 and $8 respectively for the short term. The average price target of all the analysts comes to $9.75. The estimated standard deviation from the target is $2.06.

Accuray Incorporated (ARAY) : The consensus on Accuray Incorporated (ARAY) based on 4 analyst recommendation on the company stock is 1.5, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.


Accuray Incorporated (NASDAQ:ARAY): The stock opened at $5.31 on Thursday but the bulls could not build on the opening and the stock topped out at $5.36 for the day. The stock traded down to $5.25 during the day, due to lack of any buying support eventually closed down at $5.30 with a loss of -0.56% for the day. The stock had closed at $5.33 on the previous day. The total traded volume was 584,890 shares.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.